Skip to main content
Premium Trial:

Request an Annual Quote

Avestha Gengraine, Ranbaxy Pen Drug-Discovery Deal

NEW YORK, Sept. 6 (GenomeWeb News) - Avestha Gengraine Technologies, a bioinformatics company based in India, will help Ranbaxy Laboratories develop recombinant cell lines as part of a drug-discovery program, the companies said today.

 

Avestha Gengraine's research covers infectious diseases and degenerative and metabolic disorders.

 

As GenomeWeb News reported late last month, Indian industrial conglomerate Godrej group made an investment in Bangalore-based Avestha Gengraine, according to a media repor.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.